Pittsburgh, PA (ChemImage Corporation) November 18th, 2009 - In today’s fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year’s Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.
Obtaining drug particle size information in respiratory products is important to understand the deliverable drug load, respirable fraction, and overall quality as well as from a cost perspective. Prior to entering clinical trials, this additional data can provide invaluable information, raising confidence and lowering risk of failure in vivo biostudies. The value and importance of gaining this information before taking the expensive step of beginning clinical development cannot be emphasized enough.
“We are excited to be able to provide our customers with information that can both improve the quality of their respiratory products as well as save them time and money in the long run,” said Dr. Thomas Voigt, Executive Vice President of ChemImage Corporation.
The technique uses ChemImage’s unique technology combination of Raman chemical imaging, optical microscopy, and semi-automated data gathering and analysis software to identify particles based on their unique chemistry (for example, active pharmaceutical ingredient(s) versus excipients) as well as to analyze the particle size distribution in one step. Chemical information is based on the component chemistry identified by the unique Raman signature. This technique addresses the need for a fundamental understanding of API particles in the presence of other undissolved excipients in the formulation and can be used to study ISPS, aggregation and dispersion characteristics.
“We see a growing trend in the pharmaceutical industry of orally inhaled and nasal drug products with more than one active pharmaceutical ingredient,” said Dr. Voigt. “In this case, morphological indications will not be enough to identify chemistry of particles in these formulations. Raman chemical imaging provides a much more objective method for ingredient-specific particle sizing.”
As one of the premiere meeting venues for the inhalation community, DDL provides an avenue for ChemImage to interface with researchers and business representatives regarding their product development challenges. ChemImage will be available at booth #9 to discuss chemical imaging product and service offerings.
About ChemImage
ChemImage Corporation is a world leader in hyperspectral imaging technologies, provides
instrumentation, software, lab services and expert consulting to government, industrial and academic
organizations. ChemImage offers these products and services for a range of applications including
defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Our state-of-the-art
hyperspectral technology can help to reveal critical chemical and biological information about processes,
products and services.
ChemImage’s main headquarters is located in Pittsburgh, Pennsylvania and houses research and
development laboratories as well as engineering and manufacturing facilities. ChemImage may be
contacted at +1 412-241-7335 or at www.chemimage.com.
Media Contact:
Linda Batykefer
Marketing Coordinator
Tel: 412.241.7335 ext 269
Fax: 412.241.7311
batykefer@chemimage.com
|